Evidence map›Paper›PMID 32340992›Full record

ArticleAntimicrobial agents and chemotherapy2020

Concurrent Local Delivery of Diflunisal Limits Bone Destruction but Fails To Improve Systemic Vancomycin Efficacy during Staphylococcus aureus Osteomyelitis.

Thomas J Spoonmore, Caleb A Ford, Jacob M Curry, Scott A Guelcher, James E Cassat

Open access · greenAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Repurposing Diflunisal as an Antivirulence Agent AgainstInfectious microbes & diseases · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Diflunisal-loaded poly(propylene sulfide) nanoparticles decrease S. aureus-mediated bone destruction during osteomyelitis.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2021
    Article
  7. Review
  8. Antivirulence Strategies for the Treatment ofFrontiers in microbiology · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Thomas J SpoonmoreDepartment of Chemical and Biomolecular Engineering, Vanderbilt University, Nashville, Tennessee, USA.ORCID 0000-0003-4017-2491
Caleb A FordVanderbilt Center for Bone Biology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Jacob M CurryVanderbilt Center for Bone Biology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Scott A GuelcherDepartment of Chemical and Biomolecular Engineering, Vanderbilt University, Nashville, Tennessee, USA.
James E CassatVanderbilt Center for Bone Biology, Vanderbilt University Medical Center, Nashville, Tennessee, USA jim.cassat@vumc.org.ORCID 0000-0002-1199-1167
Vanderbilt University · USVanderbilt University Medical Center · US

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM007347 · NIGMS · VANDERBILT UNIVERSITY · PI WILLIAMS, CHRISTOPHER S. · 1985 to 2023
$26.3M
Medical Scientist Training ProgramT32GM152284 · NIGMS · VANDERBILT UNIVERSITY · PI Christopher S. Williams · 2024 to 2026
$4.8M
The impact of hypoxia on Staphylococcus aureus metabolism and virulence during osteomyelitisR01AI132560 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI CASSAT, JAMES E · 2017 to 2021
$1.9M
Biofilm Dispersive Bone Grafts to Improve Healing of Contaminated FracturesR01AR064772 · NIAMS · VANDERBILT UNIVERSITY · PI GUELCHER, SCOTT A, WENKE, JOSEPH C · 2014 to 2018
$1.8M
Host-pathogen interactions during osteomyelitisK08AI113107 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI CASSAT, JAMES E · 2014 to 2018
$885k
The impact of host hypoxic signaling on antibacterial immunity and bone repair during Staphylococcus aureus osteomyelitisF30AI138424 · NIAID · VANDERBILT UNIVERSITY · PI FORD, CALEB ANTHONY · 2018 to 2022
$120k
NIAID NIH HHS F30 AI138424NIAID NIH HHS K08 AI113107NIAID NIH HHS R01 AI132560NIAMS NIH HHS R01 AR064772NIGMS NIH HHS T32 GM007347NIGMS NIH HHS T32 GM152284
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

DiflunisalOsteomyelitisStaphylococcal InfectionsAnimalsAnti-Bacterial AgentsMiceStaphylococcus aureusVancomycinAnti-Bacterial AgentsDiflunisalVancomycinantivirulencebone biologydiflunisaldrug deliveryinfectious diseaseosteomyelitisquorum quenchingquorum sensingStaphylococcus aureusvancomycin

Identifiers

PMID32340992
PMCPMC7318050
OpenAlexW3017929829

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.